Paroxetine for the prevention of depression induced by high-dose interferon alfa.

BACKGROUND Depression commonly complicates treatment with the cytokine interferon alfa-2b. Laboratory animals pretreated with antidepressants have less severe depression-like symptoms after the administration of a cytokine. We sought to determine whether a similar strategy would be effective in humans. METHODS In a double-blind study of 40 patients with malignant melanoma who were eligible for high-dose interferon alfa therapy, we randomly assigned 20 patients to receive the antidepressant paroxetine and 20 to receive placebo. The treatment was begun 2 weeks before the initiation of interferon alfa and continued for the first 12 weeks of interferon alfa therapy. RESULTS During the first 12 weeks of interferon alfa therapy, symptoms consistent with a diagnosis of major depression developed in 2 of 18 patients in the paroxetine group (11 percent) and 9 of 20 patients in the placebo group (45 percent) (relative risk, 0.24; 95 percent confidence interval, 0.08 to 0.93). Severe depression necessitated the discontinuation of interferon alfa before 12 weeks in 1 of the 20 patients in the paroxetine group (5 percent), as compared with 7 patients in the placebo group (35 percent) (relative risk, 0.14; 95 percent confidence interval, 0.05 to 0.85). The incidence of adverse events was similar in the two groups. CONCLUSIONS In patients with malignant melanoma, pretreatment with paroxetine appears to be an effective strategy for minimizing depression induced by interferon alfa.

[1]  S. Mace,et al.  Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression , 2000, Expert opinion on pharmacotherapy.

[2]  K. Miyata,et al.  Corticotropin-Releasing Hormone1 Receptors Mediate Consensus Interferon-α YM643-Induced Depression-Like Behavior in Mice , 2000 .

[3]  W. Yates,et al.  Five cases of interferon-alpha-induced depression treated with antidepressant therapy. , 1999, Psychosomatics.

[4]  A. Ravaud,et al.  Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. , 1999, The New England journal of medicine.

[5]  E. Bosmans,et al.  Negative Immunoregulatory Effects of Antidepressants: Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion , 1999, Neuropsychopharmacology.

[6]  Taylor Jl,et al.  The effects of interferon-alpha on the production and action of other cytokines. , 1998 .

[7]  P. Hauser,et al.  Mood and cognitive side effects of interferon-α therapy , 1998 .

[8]  J. Licinio,et al.  Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. , 1998, Seminars in oncology.

[9]  E. Borden,et al.  A perspective on the clinical effectiveness and tolerance of interferon-alpha. , 1998, Seminars in oncology.

[10]  D. Mohr,et al.  Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. , 1997, Archives of neurology.

[11]  F. Holsboer,et al.  Antidepressants and hypothalamic-pituitary-adrenocortical regulation. , 1996, Endocrine reviews.

[12]  R. Yirmiya.  Endotoxin produces a depressive-like episode in rats , 1996, Brain Research.

[13]  Joseph A. DiDonato,et al.  Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.

[14]  A. Valentine,et al.  Treatment of Neurotoxic Side Effects of Interferon-α with Naltrexone , 1995 .

[15]  David Collett.  Modelling Survival Data in Medical Research , 1994 .

[16]  L. Goldman,et al.  Successful treatment of interferon alfa-induced mood disorder with nortriptyline. , 1994, Psychosomatics.

[17]  H. Janssen,et al.  Suicide associated with alfa-interferon therapy for chronic viral hepatitis. , 1994, Journal of hepatology.

[18]  Levenson Jl,et al.  Fluoxetine treatment of depression caused by interferon-alpha. , 1993 .

[19]  L. Havelec,et al.  Interferon-α Stimulates the Hypothalamic- Pituitary-Adrenal Axis in vivo and in vitro , 1993 .

[20]  R. Dantzer,et al.  Sickness behavior as a new target for drug development. , 1992, Trends in pharmacological sciences.

[21]  E. Borden,et al.  Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. , 1991, Advances in experimental medicine and biology.

[22]  M. Marangolo,et al.  Depression and abnormal illness behavior in cancer patients. , 1989, General hospital psychiatry.

[23]  G. Brabant,et al.  INDUCTION OF HYPERTHYROIDISM BY INTERFERON-α-2b , 1989, The Lancet.

[24]  I. Heuser,et al.  The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. , 1988, Journal of affective disorders.

[25]  B. Carroll,et al.  The Carroll Rating Scale for Depression , 1986 .

[26]  I. Fentiman,et al.  PRIMARY HYPOTHYROIDISM ASSOCIATED WITH INTERFERON THERAPY OF BREAST CANCER , 1985, The Lancet.

[27]  B. Carroll,et al.  The Carroll Rating Scale for Depression I. Development, Reliability and Validation , 1981, British Journal of Psychiatry.

[28]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[29]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.